triple agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-25. Numbers and descriptions here follow the published literature rather than marketing material.
Retatrutide is an investigational peptide studied for obesity and type 2 diabetes. It is a single synthetic molecule designed to activate three metabolic receptors simultaneously. The compound belongs to the incretin mimetic family, a group of peptides that imitate gut hormones involved in appetite and glucose control. Its research code is LY3437943, and it remains under clinical study rather than cleared for routine medical use.
Acting as a triple agonist, the molecule binds the GLP-1, GIP, and glucagon receptors. GLP-1 activity slows gastric emptying and dampens appetite, while GIP signaling contributes to insulin sensitivity and fat metabolism. Glucagon receptor engagement raises energy expenditure and encourages fat breakdown, although it can also elevate blood glucose. Combining three pathways is intended to yield larger weight reduction than single or dual agonists, and researchers continue to examine how the balance among them shapes tolerability.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
| Property | Value | Notes |
|---|---|---|
| Molecular weight | Approximately 4,700 Da | Peptide of roughly forty amino acids |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist class |
| Research code | LY3437943 | Internal development designation |
| Compound class | Incretin mimetic peptide | Synthetic, not a biologic extract |
| Development status | Investigational | No general regulatory approval |
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
=== Kosher and halal === All Coffee Bean coffees, teas, and the powders used to make other beverages, are certified kosher. As of June 2020, Coffee Bean ended its storewide kosher-only certification for stores and bakery items in Southern California. Storewide kosher certification was ended for Coffee Bean locations in the Las Vegas area months earlier. While Coffee Bean had planned to move away from kosher-only certification to provide more offerings as a phased rollout before the COVID-19 pandemic, the company said the crisis accelerated its plan. Prior to June 2020, all company-owned locations in Southern California were certified kosher. During that time, most in California and Nevada had signed and dated certificates indicating that the entirety of their items were kosher in conformance to the standards of the certifying agency, the Kosher Supervision of America. Even before June 2020, privately owned franchise stores could opt-out of kosher certification. All the company's locations in Singapore and Malaysia are halal.
Carole Ann Bewley is an American chemist. She is a senior investigator and Chief of the Laboratory of Bioorganic Chemistry at the United States National Institute of Diabetes and Digestive and Kidney Diseases. Bewley researches secondary metabolites and basic principles involved in protein-carbohydrate interactions and how these can be exploited to engineer therapeutics.
== Effects on animals == Ecological exposure in water has severe toxic effects on wildlife. When adult and larval zebrafish were exposed to various concentrations of DBNPA, significant morphological changes and mortality rates were observed. Even relatively low concentrations of DBNPA can have detrimental effects on zebrafish embryonic development, and high concentrations resulted in rapid mortality in adult zebrafish and larvae. DBNPA is highly toxic to mammals and birds concerning acute oral inhalation, but has low toxicity to birds concerning consummation of food. The pesticide is moderately toxic to freshwater fish, estuarine fish and shrimp; moderately to highly toxic to freshwater crustaceans; and highly to very highly toxic to estuarine shellfish and larvae. Many effects to aquatic organisms occur within 24 hours of exposure. Residual antibiotics in meat were previously found to disrupt its fermentation, increase the risk of infection, and make pathogens less susceptible medically to treatment with antibiotics. Apparently, antibiotics found at low concentrations at the end of the ethanol process can cause high levels of antimicrobial resistance. These problems can be avoided by the application of DBNPA instead of an antibiotic to control bacteria in the ethanol process. This represents a significant advance in the field because DBNPA breaks down prior to the end of the process and thus cannot enter DDGS used for animal foods.
Hitchens stated, "[an] unborn child seems to me to be a real concept. It's not a growth or an appendix. You can't say the rights question doesn't come up. I don't think a woman should be forced to choose, or even can be", and, "as a materialist, I think it has been demonstrated that an embryo is a separate body and entity". Showing a desire to recognise the unborn as a life, he also affirmed a need for the right to abortion, stating, "the second-best fallback solution, which may sometimes be desirable for other reasons, is termination of pregnancy... all thinking people recognise a painful conflict of rights and interest in this question". Hitchens opposed an overturning of Roe v. Wade and instead hoped for science to develop new solutions to unwanted pregnancies "that will make abortion more like a contraceptive procedure than a surgical one." He strongly criticized the encouragement of sexual abstinence within the anti-abortion movement of the Christian right, and the equating of contraceptives to abortion, as expressed by Mother Teresa and representatives of the Roman Catholic Church.
Sources: en.wikipedia.org
== External links == Basel, Yochai; Hassner, Alfred (2001). "Imidazole and Trifluoroethanol as Efficient and Mild Reagents for Destruction of Excess Di-tert-butyl Dicarbonate [(BOC)2O]". Synthesis. 2001 (4): 0550. doi:10.1055/s-2001-12350. S2CID 97029361.
Binge drinking, or heavy episodic drinking, is drinking alcoholic beverages with an intention of becoming intoxicated by heavy consumption of alcohol over a short period of time. Specific definitions vary considerably. Binge drinking is associated with risks such as suicide, sexual assault, cardiovascular issues, and brain damage, more acutely than alcohol use in general.
== Drug delivery to the blood–brain barrier == Because of the difficulty for drugs to pass through the blood–brain barrier, a study was conducted to determine the factors that influence a compound's ability to transverse the blood–brain barrier. In this study, they examined several different factors to investigate diffusion across the blood–brain barrier. They used lipophilicity, Gibbs Adsorption Isotherm, a Co CMC Plot, and the surface area of the drug to water and air. They began by looking at compounds whose blood–brain permeability was known and labeled them either CNS+ or CNS- for compounds that easily transverse the barrier and those that did not. They then set out to analyze the above factors to determine what is necessary to transverse the blood–brain barrier. What they found was a little surprising; lipophilicity is not the leading characteristic for a drug to pass through the barrier. This is surprising because one would think that the most effective way to make a drug move through a lipophilic barrier is to increase its lipophilicity, it turns out that it is a complex function of all of these characteristics that makes a drug able to pass through the blood–brain barrier. The study found that barrier permittivity is "based on the measurement of the surface activity and as such takes into account the molecular properties of both hydrophobic and charged residues of the molecule of interest." They found that there is not a simple answer to what compounds transverse the blood–brain barrier and what does not.
=== Salomon, Levin, and Elstein === Teva's earliest predecessor was SLE, Ltd., a wholesale drug business founded in 1901 in Ottoman Empire's Mutasarrifate of Jerusalem. SLE Ltd. took its name from the initials of its three cofounders: Chaim Salomon, Moshe Levin and Yitschak Elstein, and used camels to make deliveries. During the 1930s, new immigrants from Europe founded several pharmaceutical companies including Teva and Zori. In the 1930s, Salomon, Levin, and Elstein Ltd. also founded Assia, a pharmaceutical company.
== Selected publications == Armon, A., Graur, D., & Ben-Tal, N. (2001). ConSurf: An algorithmic tool for the identification of functional regions in proteins by surface-mapping of phylogenetic information. Journal of Molecular Biology, 307, 447–463. Glaser, F., Pupko, T., Paz, I., Bell, R. E., Bechor-Shental, D., Martz, E., & Ben-Tal, N. (2003). ConSurf: Identification of functional regions in proteins by surface-mapping of phylogenetic information. Bioinformatics, 19, 163–164. Pupko, T., Bell, R. E., Mayrose, I., Glaser, F., & Ben-Tal, N. (2002). Rate4Site: An algorithmic tool for the identification of functional regions in proteins by surface mapping of evolutionary determinants within their homologues. Bioinformatics, 18, S71–S77. Ashkenazy, H., Abadi, S., Martz, E., Chay, O., Mayrose, I., Pupko, T., & Ben-Tal, N. (2016). ConSurf 2016: An improved methodology to estimate and visualize evolutionary conservation in macromolecules. Nucleic Acids Research, 44, W344–W350. Rubin, M., & Ben-Tal, N. (2021). Using ConSurf to detect functionally important regions in RNA. Current Protocols, 1, e270. Ben-Tal, N., & Kessel, A. (2010). Introduction to Proteins: Structure, Function, and Motion. Ezerzer, Y., Frenkel-Pinter, M., Kolodny, R., & Ben-Tal, N. (2025). A building blocks perspective on protein emergence and evolution. Current Opinion in Structural Biology, 91, 102996. Yariv, B., Yariv, E., Kessel, A., Masrati, G., Ben Chorin, A., Martz, E., Mayrose, I., Pupko, T., & Ben-Tal, N. (2023). Using evolutionary data to make sense of macromolecules with a “face-lifted” ConSurf.
Sources: en.wikipedia.org
==== Reserve ==== On 1 September 2014, 21 and 23 SAS were moved from UKSF. They were placed under command of 1st Intelligence, Surveillance and Reconnaissance Brigade. In 2019 they were moved back to UKSF.
==== Gomori-positive astrocytes and brain dysfunction ==== A type of astrocyte with an aging-related pathology has been described over the last fifty years. Astrocytes of this subtype possess prominent cytoplasmic granules that are intensely stained by Gomori's chrome alum hematoxylin stain, and hence are termed Gomori-positive (GP) astrocytes. They can be found throughout the brain, but are by far the most abundant in the olfactory bulbs, medial habenula, dentate gyrus of the hippocampus, arcuate nucleus of the hypothalamus, and in the dorsal medulla, just beneath the area postrema. Gomori-positive cytoplasmic granules are derived from damaged mitochondria engulfed within lysosomes. Cytoplasmic granules contain undigested remnants of mitochondrial structures. These contents include heme-linked copper and iron atoms remaining from mitochondrial enzymes. These chemical substances account for the pseudoperoxidase activity of Gomori-positive granules that can utilized to stain for these granules. Oxidative stress is believed to be cause of damage to these astrocytes. However, the exact nature of this stress is uncertain. Brain regions enriched in Gomori-positive astrocytes also contain a sub-population of specialized astrocytes that synthesize Fatty Acid Binding Protein 7 (FABP7). Indeed, astrocytes in the hypothalamus that synthesize FABP7 have also been shown to possess Gomori-positive granules. Thus, a connection between these two glial features is apparent.
== Genetics == Several genes have been implicated in the etiology of Walker–Warburg syndrome, and following genes are: POMT1, POMT2, POMGNT1, FKTN, FKRP, LARGE, CRPPA, GTDC2, DAG1, RXYLT1, B3GALNT2, POMK, B3GNT1, GMPPB. All these enzymes (except for DAG1, which is dystroglycan itself) participate in glycosylation of α-dystroglycan, which is important for the proper function of the protein. DAG1 mutations can cause either hypoglycosalation or pertubated maturation/transport to plasma membrane. First gene to cause WWS, POMT1, was discovered in 2001 by de Bernabe and colleagues.
== Sources == Raven, Peter H., Evert, Ray F., & Eichhorn, Susan E. (1986). Biology of Plants (4th ed.). New York: Worth Publishers. ISBN 087901315X. Roeckelein, Jon E. (1998). Dictionary of Theories, Laws, and Concepts in Psychology. Greenwood Publishing Group. ISBN 978-0313304606. Retrieved 1 January 2013.
Sources: en.wikipedia.org
It is a synthetic peptide classified as a triple receptor agonist. It engages the GLP-1, GIP, and glucagon receptors at once. It is investigated for metabolic and weight-related conditions rather than approved for general use.
No regulatory agency has approved it for routine medical use. It remains an investigational compound studied in controlled trials. Access outside research settings is not established.
Each receptor influences energy balance through different pathways. Combining them is intended to add fat loss from lowered intake and higher expenditure. The optimal balance among the three effects is still under study.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.